Straits Times Index
3,367.90 +29.33 (+0.88%) S&P 500
5,470.57 -4.52 (-0.08%) Dow
39,137.56 -31.96 (-0.08%) Nasdaq
17,875.14 -4.16 (-0.02%) Bitcoin USD
62,812.73 +220.29 (+0.35%) CMC Crypto 200
1,342.73 -1.77 (-0.13%)
REGN Jul 2024 1045.000 call
| Previous close | 21.97 |
| Open | 21.97 |
| Bid | 23.10 |
| Ask | 30.50 |
| Strike | 1,045.00 |
| Expiry date | 2024-07-19 |
| Day's range | 21.97 - 21.97 |
| Contract range | N/A |
| Volume | |
| Open interest | 12 |
Simply Wall St.Insiders At Regeneron Pharmaceuticals Sold US$26m In Stock, Alluding To Potential Weakness
The fact that multiple Regeneron Pharmaceuticals, Inc. ( NASDAQ:REGN ) insiders offloaded a considerable amount of...
ZacksRegeneron (REGN) Gets Positive CHMP Opinion for Lymphoma Drug
Regeneron (REGN) gets positive CHMP recommendation for odronextamab for the treatment of adults with relapsed/refractory follicular lymphoma or diffuse large B-cell lymphoma.
BenzingaWhat's Going On With Regeneron Pharmaceuticals Stock On Friday?
On Friday, Regeneron Pharmaceuticals Inc (NASDAQ:REGN) announced that the European Medicines Agency's Committee for Medicinal Products for Human Use has adopted a positive opinion recommending conditional approval of odronextamab for relapsed/refractory (R/R) follicular lymphoma (FL) or R/R diffuse large B-cell lymphoma (DLBCL), after two or more lines of systemic therapy. Relapsed/refractory (R/R) follicular lymphoma (FL) refers to cases where FL comes back after initial treatment (relapsed) or
